JanA.BurgerMD

PubMed

• 1097 citations
  Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
  Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak, Carolyn Owen
  The New England Journal of Medicine. 2015-12-16
• 266 citations
  First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leuk...
  Farhad Ravandi, Susan O'Brien, Deborah A. Thomas, Stefan Faderl, Dan Jones
  Blood. 2010-09-23
• 1714 citations
  Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
  John C. Byrd, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger
  The New England Journal of Medicine. 2013-07-03

Journal Articles

• Sustained Efficacy and Detailed Clinical Follow-up of First-Line Ibrutinib Treatment in Older Patients with Chronic Lymphocytic Leukemia: Extended Phase 3 Results from...  
  Steven Coutre, Thomas J Kipps, Jan A Burger, Nancy L Bartlett, Paul M Barr, Haematologica
• Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath stromal cells in culture.  
  18. Burger JA, M Burger, and TJ Kipps, Blood 94: 3658-3667
• Blood-derived”nurse-like” cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis via stromal cell-derived factor-1.  
  Burger JA, N Tsukada, M Burger, NJ Zvaifler, M Dell’Aquila, and TJ Kipps, Plenary Paper, Blood 96 (8) : 2655-63
• The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.  
  Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA, Blood. 2;119(5):1182-9
• The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.  
  Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA, Blood. 118(13):3603-12
• CCL3 (MIP-1?) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.  
  Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rose..., Blood.;117(5):1662-9
• B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel Syk inhibitor, R406.  
  Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda, WG, Gandhi V, Burger JA, Blood 114:1029-37
• Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in CLL: a novel therapeutic approach.  
  10. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda, WG, Keating MJ, Shokat KM, Burger JA, Blood 113:5549-57
• High-Level Expression of the T Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B cells in nurselike cell co-cultures and after BCR stimulation.  
  Burger JA, Quiroga M, Hartmann E, Bürkle A, Wierda WG, Keating MJ, and Rosenwald A, Blood 113:3050-8
• Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B cell chronic lymphocytic leukemia.  
  Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA, Blood. 110:3316-25
• CXCR4 is a prognostic marker in Acute Myelogenous Leukemia.  
  Spoo AC, Lubbert M, Wierda WG, Burger JA, Blood 109:786-791
• A Key Receptor In The Cross Talk Between Tumor Cells And Their Microenvironment.  
  Burger JA, and Kipps TJ: CXCR4, Blood 107(5): 1761-7
• Small Peptide Inhibitors of the CXCR4 Chemokine Receptor (CD184) Antagonize the Activation, Migration and Antiapoptotic Responses of CXCL12 in Chronic Lymphocytic Leuk...  
  Burger M, Hartmann T, Rawluk J, Tamamura H, Fujii N, Kipps TJ, and Burger JA, Blood 106(5):1824-30
• Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism.  
  Burger JA, NJ Zvaifler, N Tsukada, GS Firestein, and TJ Kipps, Journal of Clinical Investigation 107 (3): 305-15
• Join now to see all

Abstracts/Posters

• Expansion of T Helper Cell Subsets in Chronic Lymphocytic Leukemia Cell Co-Cultures with Nurselike Cells
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Importance of B Cell Receptor Isotypes and Stereotypes in Chronic Lymphocytic Leukemia
  Jan Burger, MD, Nature, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib Treatment Reduces Myeloid Derived Suppressor Cell Numbers and Function in Chronic Lymphocytic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all